Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Micardis Hct Generic Name & Formulations
Legal Class
Rx
General Description
Telmisartan, hydrochlorothiazide; 40mg/12.5mg, 80mg/12.5mg, 80mg/25mg; tabs.
Pharmacological Class
Angiotensin II receptor blocker (ARB) + thiazide diuretic.
How Supplied
Tabs—3x10 (blister cards)
Manufacturer
Micardis Hct Indications
Indications
Hypertension (not as initial therapy).
Micardis Hct Dosage and Administration
Adult
Not for initial therapy. May be substituted for titrated components. BP not controlled on telmisartan 80mg/day: 80mg/12.5mg once daily. BP not controlled on HCTZ 25mg/day or BP controlled but hypokalemic: 80mg/12.5mg once daily. Both: may titrate up to 160mg/25mg after 2–4 weeks. Hepatic insufficiency or biliary obstruction: initially 40mg/12.5mg once daily; monitor closely. Severe renal (CrCl ≤30mL/min) or hepatic impairment: not recommended.
Children
Not established.
Micardis Hct Contraindications
Contraindications
Anuria. Sulfonamide allergy. Concomitant aliskiren in patients with diabetes.
Micardis Hct Boxed Warnings
Boxed Warning
Fetal toxicity.
Micardis Hct Warnings/Precautions
Warnings/Precautions
Fetal toxicity may develop; discontinue if pregnancy is detected. Salt/volume depletion; correct hypovolemia prior to initiation. Severe CHF. Renal or hepatic impairment. Renal artery stenosis. Asthma. Diabetes. Postsympathectomy. SLE. Gout. Acute myopia. Secondary angle-closure glaucoma. Monitor BP, electrolytes, and renal function. Elderly. Neonates. Pregnancy: avoid. Nursing mothers: not recommended.
Micardis Hct Pharmacokinetics
See Literature
Micardis Hct Interactions
Interactions
See Contraindications. Concomitant ACE inhibitors (eg, ramipril): not recommended. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). Digoxin, lithium toxicity. Adjust antidiabetic medications. Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. Hypokalemia with corticosteroids, ACTH. Orthostatic hypotension potentiated by alcohol, CNS depressants. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors (monitor renal function periodically in elderly and/or volume-depleted). Potentiates other antihypertensives. May potentiate nondepolarizing muscle relaxants. May antagonize pressor amines. Reduced absorption with bile acid resins (eg, cholestyramine, colestipol). May interfere with parathyroid test.
Micardis Hct Adverse Reactions
Adverse Reactions
Upper respiratory tract infection, dizziness, sinusitis, diarrhea, fatigue, flu-like symptoms, back or abdominal pain, dyspepsia, erythema, vomiting, bronchitis, pharyngitis; electrolyte disturbances, orthostatic hypotension, hyperglycemia, hyperuricemia, adverse lipid values, angioedema, rhabdomyolysis (rare); HCTZ: increased risk for non-melanoma skin cancer.
Micardis Hct Clinical Trials
See Literature
Micardis Hct Note
Not Applicable
Micardis Hct Patient Counseling
See Literature
